{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-25-000109","form_type":"8-K/A","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.547265+00:00","generated_at":"2026-05-17T00:47:48.225853+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Myriad Genetics Q3 revenue $205.7M (-4% YoY); adjusted EPS $0.00; reaffirms FY2025 guidance","bullets":["Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M headwinds (UNH GeneSight loss, EndoPredict divestiture).","GAAP net loss $27.4M ($0.29 loss); adjusted EPS $0.00; adjusted EBITDA $10.3M.","Hereditary cancer testing volume +11% YoY; GeneSight revenue -19% YoY due to UnitedHealthcare coverage change.","Entered strategic CDx collaboration with SOPHiA GENETICS for liquid biopsy companion diagnostics.","Reiterates FY2025 revenue $818-828M, gross margin 69.5-70%, adjusted EBITDA $27-33M."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-25-000109","json":"https://secwatch.observer/filing/0000899923-25-000109.json","markdown":"https://secwatch.observer/filing/0000899923-25-000109.md","text":"https://secwatch.observer/filing/0000899923-25-000109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992325000109/0000899923-25-000109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992325000109/mygn-20251103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:47:48.225853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}